SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) February 9, 1999
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technologies, Inc. (OTCBB:BICO) announced
today that it has received a purchase order from the US
Food and Drug Administration (FDA) to purchase a
Diasensor1000 Noninvasive Blood Glucose Monitor.
Biocontrol Technology scientific and engineering personnel
will conduct a seminar to educate the FDA staff on the use
and maintenance of this particular instrument so they can
evaluate its performance characteristics and conduct laboratory
research on noninvasive monitoring. The Diasensor 1000 is a
home-use instrument used by patients with diabetes to measure
their blood glucose without the need to prick the finger to
obtain a drop of blood.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired -
Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: February 9, 1999
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
FDA ORDERS DIASENSOR 1000 FROM BIOCONTROL TECHNOLOGY, INC.
Pittsburgh, PA - February 9, 1999 - Biocontrol Technology,
Inc. (OTCBB:BICO) announced today that it has received a purchase
order from the US Food and Drug Administration (FDA) to purchase
a Diasensorr1000 Noninvasive Blood Glucose Monitor. The FDA's
intent is not to use the Diasensor 1000 in the type of clinical
investigation to support market authorization but to gain
knowledge of the performance of such devices over their full
range of performance.
Biocontrol Technology scientific and engineering personnel
will conduct a seminar to educate the FDA staff on the use and
maintenance of this particular instrument so they can evaluate
its performance characteristics and conduct laboratory research
on noninvasive monitoring.
The Diasensor 1000 is a home-use instrument used by patients
with diabetes to measure their blood glucose without the need to
prick the finger to obtain a drop of blood. Patients using
currently marketed invasive devices require that patients prick
their fingers to obtain a sample of blood to test their glucose.
The Diasensor 1000 illuminates a small area on the patient's arm
with infrared light, which is then scattered back out through the
skin and collected by the instrument. This information is
interpreted by software in the instrument as a blood glucose
concentration.
Although not approved for sale in the US, the Diasensor 1000
is currently being marketed in the 15-nation European Union where
it has been approved.
Biocontrol Technology has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products. Subsidiary
Diasensor.com, Inc., also located in Pittsburgh, PA, markets the
Diasensor. Diasensor.com owns the patent, marketing and
distribution rights to the sensor while Biocontrol has the
exclusive rights to the research and development and
manufacturing of the sensor.
WEBSITE: www.bico.com
INVESTOR RELATIONS NEWSLINE NUMBER: 1.800.357.6204
